September 23, 2019
On September 19, 2019, Torrent Pharmaceutical announced an expanded recall of specific lots of Losartan tablets (50mg and 100mg), and Losartan/hydrochlorothiazide tablets (50mg/12.5mg and 100mg/25mg) due to the detection of an unexpected impurity (NMBA) found in the active pharmaceutical ingredient.
Losartan Potassium Tablets, USP 50mg, lot # 4DU2E009, exp 12/31/2020, NDC 13668-409-10 Losartan Potassium Tablets, USP 100mg, lot# 4DU3E009, exp 12/31/2020, NDC 13668-115-90 Losartan Potassium Tablets, USP 100mg, lot # 4DU3D018, exp 02/28/2021, NDC 13668-115-10 Losartan Potassium / Hydrochlorothiazide Tablets, USP 50mg/12.5mg, lot# BEF7D051, exp 11/30/2020, NDC 13668-116-90 *Losartan Potassium / Hydrochlorothiazide Tablets, USP 100mg/25mg, lot # 4P04D007, exp 07/31/2020, NDC 13668-118-90
Additional information is available on the FDA's website:
Last updated: March 13, 2020